These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 7699664)

  • 41. Criteria for the definition of the eosinophilia-myalgia syndrome.
    Hertzman PA
    J Rheumatol Suppl; 1996 Oct; 46():7-12. PubMed ID: 8895176
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Presence of peak X and related compounds: the reported contaminant in case related 5-hydroxy-L-tryptophan associated with eosinophilia-myalgia syndrome.
    Johnson KL; Klarskov K; Benson LM; Williamson BL; Gleich GJ; Naylor S
    J Rheumatol; 1999 Dec; 26(12):2714-7. PubMed ID: 10606395
    [No Abstract]   [Full Text] [Related]  

  • 43. Dyspnea and pulmonary function in the L-tryptophan-associated eosinophilia-myalgia syndrome.
    Read CA; Clauw D; Weir C; Da Silva AT; Katz P
    Chest; 1992 May; 101(5):1282-6. PubMed ID: 1582285
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Abnormalities of the coronary arteries, neural structures and conduction system of the heart observed postmortem in the eosinophilia-myalgia syndrome, with a discussion of comparative findings from the toxic oil syndrome.
    James TN
    Trans Am Clin Climatol Assoc; 1991; 102():52-81; discussion 81-3. PubMed ID: 2130570
    [No Abstract]   [Full Text] [Related]  

  • 45. Eosinophilia-myalgia syndrome and peripheral eosinophilia.
    Schwartzberg M; Weber CA
    J Rheumatol; 1991 Dec; 18(12):1940-1. PubMed ID: 1795341
    [No Abstract]   [Full Text] [Related]  

  • 46. Eosinophilia-myalgia syndrome and fasciitis with an active alveolitis.
    Chauhan D; Mengel CE
    Kans Med; 1993 Jun; 94(6):175-7. PubMed ID: 8355447
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Epidemiologic studies of the association of L-tryptophan with the eosinophilia-myalgia syndrome: a critique.
    Shapiro S
    J Rheumatol Suppl; 1996 Oct; 46():44-58; discussion 58-9. PubMed ID: 8895181
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 1,1'-Ethylidenebis[L-tryptophan], an impurity in L-tryptophan associated with eosinophilia-myalgia syndrome, stimulates type I collagen gene expression in human fibroblasts in vitro.
    Zangrilli JG; Mayeno AN; Vining V; Varga J
    Biochem Mol Biol Int; 1995 Nov; 37(5):925-33. PubMed ID: 8624499
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dermal mucinosis in the eosinophilia-myalgia syndrome.
    Farmer KL; Hebert AA; Rapini RP; Jordan RE
    Arch Dermatol; 1990 Nov; 126(11):1518-20. PubMed ID: 2241211
    [No Abstract]   [Full Text] [Related]  

  • 50. [Scleroderma, scleroderma related diseases].
    Kondo H
    Ryoikibetsu Shokogun Shirizu; 2000; (31):494-9. PubMed ID: 11269145
    [No Abstract]   [Full Text] [Related]  

  • 51. Tryptophan produced by Showa Denko and epidemic eosinophilia-myalgia syndrome.
    Kilbourne EM; Philen RM; Kamb ML; Falk H
    J Rheumatol Suppl; 1996 Oct; 46():81-8; discussion 89-91. PubMed ID: 8895184
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Treatment of chronic eosinophilia-myalgia syndrome--effective therapy regimens become evident].
    Schnabel A; Arlt AC; Gross WL
    Z Rheumatol; 1992; 51(4):155-7. PubMed ID: 1414038
    [No Abstract]   [Full Text] [Related]  

  • 53. Neuromuscular disease management and rehabilitation, part II: specialty care and therapeutics.
    McDonald CM; Joyce NC
    Phys Med Rehabil Clin N Am; 2012 Nov; 23(4):xiii-xvii. PubMed ID: 23137747
    [No Abstract]   [Full Text] [Related]  

  • 54. Eosinophilia-myalgia syndrome: the aftermath.
    Sack KE; Criswell LA
    South Med J; 1992 Sep; 85(9):878-82. PubMed ID: 1523446
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Animal models of the eosinophilia-myalgia syndrome.
    Clauw DJ
    J Rheumatol Suppl; 1996 Oct; 46():93-7; discussion 92, 97-8. PubMed ID: 8895185
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [L-tryptophan and eosinophilia-myalgia syndrome].
    Hansen TM
    Ugeskr Laeger; 1990 Jul; 152(30):2151. PubMed ID: 2399584
    [No Abstract]   [Full Text] [Related]  

  • 57. Physical Medicine and Rehabilitation Clinics of North America. Neuromuscular disease management and rehabilitation, part II: specialty care and therapeutics. Foreword.
    Carter GT
    Phys Med Rehabil Clin N Am; 2012 Nov; 23(4):xi-xii. PubMed ID: 23137746
    [No Abstract]   [Full Text] [Related]  

  • 58. Risk factors for developing eosinophilia myalgia syndrome among L-tryptophan users in New York.
    Back EE; Henning KJ; Kallenbach LR; Brix KA; Gunn RA; Melius JM
    J Rheumatol; 1993 Apr; 20(4):666-72. PubMed ID: 8496862
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intimidation of researchers by special-interest groups.
    Sternberg EM
    N Engl J Med; 1997 Oct; 337(18):1316; author reply 1316-7. PubMed ID: 9380084
    [No Abstract]   [Full Text] [Related]  

  • 60. The natural history of eosinophilia-myalgia syndrome in a tryptophan-exposed cohort in South Carolina.
    Sullivan EA; Kamb ML; Jones JL; Meyer P; Philen RM; Falk H; Sinks T
    Arch Intern Med; 1996 May; 156(9):973-9. PubMed ID: 8624177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.